Baird analyst Eric Coldwell said they have long posited that Cardinal Health could well absorb the loss of OptumRx given strong underlying market fundamentals, recent performance, and solid BS/CF generation; and it was confirmed today by reiteration of long-term objectives. Baird believe that valuation remains attractive and theu maintain their Outperform rating and $134 price target on Cardinal Health shares.